Background: Cardiac macrophages (cMacs) have been implicated in myocardial repair following myocardial infarction (MI), yet their therapeutic potential in ischaemic cardiomyopathy (ICM) remains limited by an incomplete understanding of their molecular regulation. Cluster of Differentiation 163 (CD163) is highly expressed in these macrophages, yet its functional role in regulating post-MI cardiac repair remains unknown.
Methods: A cross-sectional clinical study was conducted to assess the association between circulating soluble CD163 concentration and heart failure due to ICM. To investigate the functional contribution of CD163 in ICM, wild-type (WT) and Cd163−/− mice were subjected to permanent ligation of the left anterior descending coronary artery. Single-cell RNA sequencing was employed to analyse transcriptional changes in cardiac immune cells. Recombinant osteopontin (OPN) and CD163 were administered to assess their therapeutic effect in Cd163−/− mice.
Results: Circulating soluble CD163 levels were markedly elevated in patients with ICM-induced heart failure compared with individuals without heart failure (median difference 34.5 ng/mL, IQR 13.6–54.6 ng/mL, p = .002) and showed a positive correlation with the extent of systolic dysfunction and left ventricular (LV) dilation. Cd163−/− mice displayed aggravated LV systolic dysfunction, reduced ejection fraction and fractional shortening, impaired myocardial strain and reduced relative wall thickness post-MI. Recombinant CD163 protein could reverse systolic dysfunction and LV dilation in Cd163−/− mice after MI. CD163 was predominantly expressed in CCR2− resident cMacs, and CD163 deficiency altered transcriptional programmes of macrophages without affecting their polarization status, with enrichment in cytokine signalling and extracellular matrix-related pathways. Spp1 (OPN) expression was significantly downregulated in Cd163−/− hearts under both sham and MI conditions. Administration of recombinant OPN improved systolic function, reduced ventricular dilation, decreased fibrotic scar size and restored the elastin-to-collagen ratio in Cd163−/− mice.
Conclusions: In cMacs, CD163 contributes to post-MI repair by upregulating OPN expression, which in turn helps maintain systolic function.
Key points:
| [1] |
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023; 147: e93-e621.
|
| [2] |
Cabac-Pogorevici I, Muk B, Rustamova Y, et al. Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. Eur J Heart Fail. 2020; 22: 789-799.
|
| [3] |
Liga R, Colli A, Taggart DP, et al. Myocardial revascularization in patients with ischemic cardiomyopathy: for whom and how. J Am Heart Assoc. 2023; 12:e026943.
|
| [4] |
Yap J, Irei J, Lozano-Gerona J, et al. Macrophages in cardiac remodelling after myocardial infarction. Nat Rev Cardiol. 2023; 20: 373-385.
|
| [5] |
Shinde AV, Frangogiannis NG. Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol. 2014; 70: 74-82.
|
| [6] |
Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016; 119: 91-112.
|
| [7] |
Hume RD, Kanagalingam S, Deshmukh T, et al. Tropoelastin improves post-infarct cardiac function. Circ Res. 2023; 132: 72-86.
|
| [8] |
Mizuno T, Yau TM, Weisel RD, et al. Elastin stabilizes an infarct and preserves ventricular function. Circulation. 2005; 112: I81-88.
|
| [9] |
Bajpai G, Bredemeyer A, Li W, et al. Tissue resident CCR2− and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res. 2019; 124: 263-278.
|
| [10] |
Leblond A-L, Klinkert K, Martin K, et al. Systemic and cardiac depletion of M2 macrophage through CSF-1R signaling inhibition alters cardiac function post myocardial infarction. PLoS One. 2015; 10:e0137515.
|
| [11] |
Shiraishi M, Shintani Y, Shintani Y, et al. Alternatively activated macrophages determine repair of the infarcted adult murine heart. J Clin Invest. 2016; 126: 2151-2166.
|
| [12] |
Chen R, Zhang H, Tang B, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024; 9: 130.
|
| [13] |
Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart. JACC Basic Transl Sci. 2019; 4: 449-467.
|
| [14] |
Zhang S, Zhang Y, Duan X, et al. Targeting NPM1 epigenetically promotes postinfarction cardiac repair by reprogramming reparative macrophage metabolism. Circulation. 2024; 149: 1982-2001.
|
| [15] |
Wang Q, Ismahil MA, Zhu Y, et al. CD206+IL-4Rα+ macrophages are drivers of adverse cardiac remodeling in ischemic cardiomyopathy. Circulation. 2025; 152: 257-273.
|
| [16] |
Chen L, Mei W, Song J, et al. CD163 protein inhibits lipopolysaccharide-induced macrophage transformation from M2 to M1 involved in disruption of the TWEAK-Fn14 interaction. Heliyon. 2024; 10:e23223.
|
| [17] |
Etzerodt A, Rasmussen MR, Svendsen P, et al. Structural basis for inflammation-driven shedding of CD163 ectodomain and tumor necrosis factor-α in macrophages. J Biol Chem. 2014; 289: 778-788.
|
| [18] |
Durda P, Raffield LM, Lange EM, et al. Circulating soluble CD163, associations with cardiovascular outcomes and mortality, and identification of genetic variants in older individuals: the Cardiovascular Health Study. J Am Heart Assoc. 2022; 11:e024374.
|
| [19] |
Ni W, Ge X, Liu Y, et al. CD163+ macrophages attenuate pressure overload-induced left ventricular systolic dysfunction and cardiac mitochondrial dysfunction via interleukin-10. Basic Res Cardiol. 2025; 120: 727-744.
|
| [20] |
Dai C, Yao X, Gordon EM, et al. A CCL24-dependent pathway augments eosinophilic airway inflammation in house dust mite-challenged Cd163−/− mice. Mucosal Immunol. 2016; 9: 702-717.
|
| [21] |
Gao E, Lei YH, Shang X, et al. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res. 2010; 107: 1445-1453.
|
| [22] |
Kucherenko MM, Sang P, Yao J, et al. Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease. Nat Commun. 2023; 14: 4416.
|
| [23] |
Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9: 676-682.
|
| [24] |
Liu B, Maekawa T, Yoshida K, et al. Telomere shortening by transgenerational transmission of TNF-α-induced TERRA via ATF7. Nucleic Acids Res. 2019; 47: 283-298.
|
| [25] |
Kim D, Paggi JM, Park C, et al. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019; 37: 907-915.
|
| [26] |
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014; 30: 923-930.
|
| [27] |
McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45: 3912-4018.
|
| [28] |
Rickham PP. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J. 1964; 2: 177.
|
| [29] |
Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011; 58: 1733-1740.
|
| [30] |
Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal. 2013; 18: 2352-2363.
|
| [31] |
Smiseth OA, Torp H, Opdahl A, et al. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. 2016; 37: 1196-1207.
|
| [32] |
Zhou RX, Higgins MK. Scavenger receptor CD163 multimerises to allow uptake of diverse ligands. Nat Commun. 2025; 16: 6623.
|
| [33] |
De Bei O, Campanini B. Strength in numbers: how multimerization drives HpHb uptake by CD163 scavenging receptor. Nat Commun. 2025; 17: 111.
|
| [34] |
Dick SA, Macklin JA, Nejat S, et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat Immunol. 2019; 20: 29-39.
|
| [35] |
Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001; 88: 1080-1087.
|
| [36] |
Santos-Zas I, Lemarié J, Zlatanova I, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021; 12: 1483.
|
| [37] |
Rotem I, Konfino T, Caller T, et al. Osteopontin promotes infarct repair. Basic Res Cardiol. 2022; 117: 51.
|
| [38] |
Liang X, Luo J, Zhou Q, et al. Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression. Gut. 2026; 75: 367-381.
|
| [39] |
Hergel LLF, Kielsen K, Weischendorff S, et al. The macrophage activation marker sCD163 in acute and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023; 58: 587-589.
|
| [40] |
Yap Y-J, Wong P-F, AbuBakar S, et al. The clinical utility of CD163 in viral diseases. Clin Chim Acta. 2023; 541:117243.
|
| [41] |
Plevriti A, Lamprou M, Mourkogianni E, et al. The role of soluble CD163 (sCD163) in human physiology and pathophysiology. Cells. 2024; 13: 1679.
|
| [42] |
Schack L, Stapulionis R, Christensen B, et al. Osteopontin enhances phagocytosis through a novel osteopontin receptor, the alphaXbeta2 integrin. J Immunol. 2009; 182: 6943-6950.
|
| [43] |
Shin Y-J, Kim HL, Choi J-S, et al. Osteopontin: correlation with phagocytosis by brain macrophages in a rat model of stroke. Glia. 2011; 59: 413-423.
|
| [44] |
Ding W, Deng S, Wang Z, et al. CD163+ macrophages drive rapid pulmonary fibrosis via osteopontin secretion. Int Immunopharmacol. 2025; 161:114976.
|
| [45] |
Yang Y-E, Lin Y-A, Ling L-L, et al. Rab37-mediated OPN secretion enriches SPP1+ macrophages through autocrine-paracrine signaling to drive lung tumor progression. Oncogenesis. 2026; 15: 4.
|
| [46] |
Shirakawa K, Endo J, Kataoka M, et al. IL (interleukin)-10-STAT3-galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction. Circulation. 2018; 138: 2021-2035.
|
| [47] |
Shinohara ML, Jansson M, Hwang ES, et al. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci USA. 2005; 102: 17101-17106.
|
| [48] |
Lichtenauer M, Mildner M, Baumgartner A, et al. Intravenous and intramyocardial injection of apoptotic white blood cell suspensions prevents ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarction. Basic Res Cardiol. 2011; 106: 645-655.
|
| [49] |
Xie Z, Singh M, Siwik DA, et al. Osteopontin inhibits interleukin-1beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: role of protein kinase C-zeta. J Biol Chem. 2003; 278: 48546-48552.
|
| [50] |
Krishnamurthy P, Peterson JT, Subramanian V, et al. Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol Cell Biochem. 2009; 322: 53-62.
|
| [51] |
Satoh M, Nakamura M, Akatsu T, et al. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail. 2005; 7: 755-762.
|
| [52] |
Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res. 2014; 102: 240-248.
|
| [53] |
Ilatovskaya DV, Pitts C, Clayton J, et al. CD8+ T-cells negatively regulate inflammation post-myocardial infarction. Am J Physiol Heart Circ Physiol. 2019; 317: H581-H596.
|
| [54] |
Zhang L, Wang S, Ding Y, et al. Macrophage-TREM2 promotes cardiac repair by restricting the infiltration of CD8+ T cells via CXCL16-CXCR6 axis after myocardial infarction. Theranostics. 2025; 15: 9580-9600.
|
RIGHTS & PERMISSIONS
2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF
(11024KB)
